Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor-associated DNA , both in Circulating Tumor Cells and in plasma (cell-free circulating tumor DNA). The Company's mission is to improve outcomes for cancer patients by advancing oncology diagnostics. Biocept utilizes patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. Additionally, the Company offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. Biocept's strategic focus is to promote its unique technology (CEE, cell enrichment and extraction) and family of laboratory tests (OncoCEE) to the Oncology Community. 

The CEE system has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. Examples of these rare cells are circulating tumor cells in patients with early-stage, metastatic or recurrent cancers. Biocept provides products and services to detect and analyze these rare cells in order to provide information that physicians can use to make treatment decisions. The Company employs its unique laboratory tests through an offering of services to medical/surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical/clinical researchers.

Company Growth (employees)
San Diego, US
Size (employees)
42 (est)
Biocept was founded in 1993 and is headquartered in San Diego, US

Key People/Management at Biocept

Michael W. Wallace

Michael W. Wallace

President & CEO
Lyle Arnold

Lyle Arnold


Biocept Office Locations

Biocept has an office in San Diego
San Diego, US (HQ)
5810 Nancy Ridge Dr

Biocept Financials and Metrics

Biocept Financials


Market capitalization (13-Dec-2017)

20.9 m
Biocept's current market capitalization is $20.9 m.
USDFY, 2014FY, 2015FY, 2016

Net Income

(15.9 m)(16.9 m)(18.4 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


76.8 k164.9 k221.4 k662.9 k1 m1.7 m1.3 m

Cost of goods sold

985.2 k1.2 m1.5 m1.7 m1.9 m2.1 m2.4 m2.5 m

Gross profit

(908.5 k)(994.9 k)(1.3 m)(1 m)(829 k)(446.4 k)(1.1 m)

Gross profit Margin, %

USDFY, 2014FY, 2015FY, 2016


5.4 m8.8 m4.6 m

Accounts Receivable

10.6 k34.2 k129 k


338.7 k435.9 k484.6 k

Current Assets

5.9 m9.6 m5.8 m
USDQ3, 2017


412.9 k

Accounts Payable

1.6 m
    USDFY, 2014FY, 2015FY, 2016

    Net Income

    (15.9 m)(16.9 m)(18.4 m)

    Depreciation and Amortization

    251.2 k261.4 k322 k

    Accounts Receivable

    (1.4 k)(23.6 k)(94.8 k)


    (401.4 k)(80.4 k)494.7 k
    USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Accounts Receivable

    15.6 k32.1 k40.4 k43.4 k86.7 k85.7 k834.9 k994.7 k


    412.9 k

    Accounts Payable

    970.5 k612.5 k766.4 k853.3 k946.3 k1.7 m1.4 m1.8 m1.6 m
      Show all financial metrics

      Biocept Market Value History

      Biocept's Web-traffic and Trends

      Biocept Online and Social Media Presence

      Biocept News and Updates

      Future of Liquid Biopsy market discussed in new Study

      Market research future published a Cooked research report on global liquid biopsy market. The global liquid biopsy market is expected to grow at a CAGR of ~ 28% during the period of 2015 to 2022. Posted via Industry Today. Follow us on Twitter @IndustryToday

      Liquid Biopsy Market to Garner US$ 2.89 Bn by 2026 End

      Future Market Insights has announced the addition of the “Liquid Biopsy Market: Global Industry Analysis and Opportunity Assessment, 2016-2026"report to their offering. Posted via Industry Today. Follow us on Twitter @IndustryToday

      Biocept Company Life and Culture

      You may also be interested in